Vanda Pharmaceuticals (NASDAQ: VNDA) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Vanda Pharmaceuticals to similar businesses based on the strength of its risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.
Insider and Institutional Ownership
88.5% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 7.6% of Vanda Pharmaceuticals shares are owned by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares Vanda Pharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Vanda Pharmaceuticals||$146.02 million||-$18.01 million||-44.74|
|Vanda Pharmaceuticals Competitors||$284.30 million||$34.29 million||139.97|
Vanda Pharmaceuticals’ competitors have higher revenue and earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Vanda Pharmaceuticals has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals’ competitors have a beta of 5.85, indicating that their average stock price is 485% more volatile than the S&P 500.
This is a breakdown of recent ratings and recommmendations for Vanda Pharmaceuticals and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Vanda Pharmaceuticals Competitors||839||3190||11556||230||2.71|
Vanda Pharmaceuticals currently has a consensus price target of $22.20, indicating a potential upside of 60.06%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.50%. Given Vanda Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts clearly believe Vanda Pharmaceuticals is more favorable than its competitors.
This table compares Vanda Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Vanda Pharmaceuticals Competitors||-5,339.82%||-435.75%||-40.59%|
Vanda Pharmaceuticals beats its competitors on 7 of the 12 factors compared.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.